Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000876247 | SCV001018798 | likely benign | Nemaline myopathy 2 | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003141884 | SCV003809594 | uncertain significance | not provided | 2021-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004027873 | SCV004979023 | uncertain significance | Inborn genetic diseases | 2021-11-23 | criteria provided, single submitter | clinical testing | The c.17005C>G (p.P5669A) alteration is located in exon 123 (coding exon 121) of the NEB gene. This alteration results from a C to G substitution at nucleotide position 17005, causing the proline (P) at amino acid position 5669 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000876247 | SCV001456479 | uncertain significance | Nemaline myopathy 2 | 2020-01-17 | no assertion criteria provided | clinical testing |